<SEC-DOCUMENT>0001562180-24-002130.txt : 20240304
<SEC-HEADER>0001562180-24-002130.hdr.sgml : 20240304
<ACCEPTANCE-DATETIME>20240304180128
ACCESSION NUMBER:		0001562180-24-002130
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240301
FILED AS OF DATE:		20240304
DATE AS OF CHANGE:		20240304

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Huang Jane
		CENTRAL INDEX KEY:			0001683913
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39527
		FILM NUMBER:		24716877

	MAIL ADDRESS:	
		STREET 1:		C/O MOURANT OZANNES CORPORATE SERVICES
		STREET 2:		94 SOLARIS AVENUE
		CITY:			CAMANA BAY, GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prelude Therapeutics Inc
		CENTRAL INDEX KEY:			0001678660
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811384762
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		175 INNOVATION BOULEVARD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805
		BUSINESS PHONE:		(302) 467-1280

	MAIL ADDRESS:	
		STREET 1:		175 INNOVATION BOULEVARD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prelude Therapeutics Inc.
		DATE OF NAME CHANGE:	20160630
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primarydocument.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-03-01</periodOfReport>

    <notSubjectToSection16>false</notSubjectToSection16>

    <issuer>
        <issuerCik>0001678660</issuerCik>
        <issuerName>Prelude Therapeutics Inc</issuerName>
        <issuerTradingSymbol>PRLD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001683913</rptOwnerCik>
            <rptOwnerName>Huang Jane</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PRELUDE THERAPEUTICS INCORPORATED</rptOwnerStreet1>
            <rptOwnerStreet2>175 INNOVATION BOULEVARD</rptOwnerStreet2>
            <rptOwnerCity>WILMINGTON</rptOwnerCity>
            <rptOwnerState>DE</rptOwnerState>
            <rptOwnerZipCode>19805</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>President, CMO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.59</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-03-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>175000.00</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-02-28</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>175000.00</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>175000.00</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Laurent Chardonnet, Attorney-in-Fact</signatureName>
        <signatureDate>2024-03-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
